ARS Pharmaceuticals/$SPRY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About ARS Pharmaceuticals
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.
Ticker
$SPRY
Sector
Primary listing
Employees
157
Headquarters
Website
SPRY Metrics
BasicAdvanced
$974m
-
-$2.00
0.80
-
Price and volume
Market cap
$974m
Beta
0.8
52-week high
$18.90
52-week low
$6.66
Average daily volume
1.7m
Financial strength
Current ratio
4.943
Quick ratio
4.645
Long term debt to equity
279.238
Total debt to equity
279.238
Interest coverage (TTM)
-40.16%
Profitability
EBITDA (TTM)
-200.932
Gross margin (TTM)
59.41%
Net profit margin (TTM)
-200.00%
Operating margin (TTM)
-204.49%
Effective tax rate (TTM)
0.04%
Revenue per employee (TTM)
$630,000
Management effectiveness
Return on assets (TTM)
-41.15%
Return on equity (TTM)
-136.40%
Valuation
Price to revenue (TTM)
9.799
Price to book
15.89
Price to tangible book (TTM)
20.67
Price to free cash flow (TTM)
-5.533
Free cash flow yield (TTM)
-18.07%
Free cash flow per share (TTM)
-1.773
Growth
Revenue change (TTM)
1.92%
Earnings per share change (TTM)
1,146.57%
3-year revenue growth (CAGR)
427.86%
3-year earnings per share growth (CAGR)
38.28%
What the Analysts think about SPRY
Analyst ratings (Buy, Hold, Sell) for ARS Pharmaceuticals stock.
SPRY Financial Performance
Revenues and expenses
SPRY Earnings Performance
Company profitability
SPRY News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs